Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8864519rdf:typepubmed:Citationlld:pubmed
pubmed-article:8864519lifeskim:mentionsumls-concept:C0018801lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C0012984lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C0034052lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C0027481lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:8864519lifeskim:mentionsumls-concept:C0439596lld:lifeskim
pubmed-article:8864519pubmed:issue8lld:pubmed
pubmed-article:8864519pubmed:dateCreated1997-1-6lld:pubmed
pubmed-article:8864519pubmed:abstractText1. Pacing-induced congestive heart failure (CHF) in dogs is associated with increased plasma levels of atrial natriuretic factor (ANF) and inhibition of receptor-mediated cyclic AMP-dependent relaxation in isolated pulmonary arteries (PA). Since ANF is known to be negatively coupled to adenylate cyclase, we studied cyclic AMP-mediated relaxation to isoprenaline (Iso) and arachidonic acid (AA) in PA from control dogs (C), dogs with pacing-induced CHF (CHF) and dogs with bilateral atrial appendectomy and CHF (ATR APP+CHF). 2. In CHF, plasma ANF levels increased from a baseline of 80 +/- 8 pg ml-1 to 283 +/- 64 pg ml-1 (P < 0.05), but the ATR APP+CHF group failed to show this increase (67 +/- 7 pg ml-1 vs 94 +/- 15 pg ml-1, P = NS). Plasma ANF levels, however, did not influence myocardial dysfunction in CHF. 3. The relaxation of 49 +/- 5% to 1 microM Iso in C was reduced to 23 +/- 4% in CHF (P < 0.05), but relaxation of 49 +/- 12% was observed in the ATR APP+CHF group (P = NS vs C). Relaxation responses to 10 microM AA were as follows: 77 +/- 5% (C, n = 8), 27 +/- 8% (CHF, n = 10, P < 0.05 vs C), and 93 +/- 5% (ATR APP+CHF, n = 5). The presence of CHF, or the plasma ANF levels, did not affect responses to cyclic GMP-mediated relaxing agents in PA. 4. These data indicate that the myocardial performance in CHF is not influenced by plasma ANF levels. However, altered cyclic AMP-mediated relaxation in PA during CHF is, in part, modulated by circulating ANF levels.lld:pubmed
pubmed-article:8864519pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:languageenglld:pubmed
pubmed-article:8864519pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:citationSubsetIMlld:pubmed
pubmed-article:8864519pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8864519pubmed:statusMEDLINElld:pubmed
pubmed-article:8864519pubmed:monthAuglld:pubmed
pubmed-article:8864519pubmed:issn0007-1188lld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:WangJJlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:MathewRRlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:GewitzM HMHlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:HintzeT HTHlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:ShenWWlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:WolinM SMSlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:OmarH AHAlld:pubmed
pubmed-article:8864519pubmed:authorpubmed-author:FayngershRRlld:pubmed
pubmed-article:8864519pubmed:issnTypePrintlld:pubmed
pubmed-article:8864519pubmed:volume118lld:pubmed
pubmed-article:8864519pubmed:ownerNLMlld:pubmed
pubmed-article:8864519pubmed:authorsCompleteYlld:pubmed
pubmed-article:8864519pubmed:pagination1886-90lld:pubmed
pubmed-article:8864519pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:meshHeadingpubmed-meshheading:8864519-...lld:pubmed
pubmed-article:8864519pubmed:year1996lld:pubmed
pubmed-article:8864519pubmed:articleTitleModulation by atrial natriuretic factor of receptor-mediated cyclic AMP-dependent responses in canine pulmonary artery during heart failure.lld:pubmed
pubmed-article:8864519pubmed:affiliationDepartment of Paediatrics, New York Medical College, Valhalla 10595, USA.lld:pubmed
pubmed-article:8864519pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8864519pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8864519pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed